| Patient | Barbara Jordan |
|---|---|
| Date of birth | 1982-02-21 |
| Identifiers | MRN HR-ML030-SYN; SSN (made up) 000-30-6852 |
| Document date | 2026-08-17 |
| Author | Evangeline Moss, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Ms. Jordan is a 44-year-old professor with active primary progressive multiple sclerosis who comes for her yearly preventive visit seven weeks after her four-month review. She had her two ocrelizumab half-doses three months ago and has had no infections since. Her walking is unchanged: she uses her cane on campus and a rollator at home for longer distances. The summer heat makes her legs heavier by the afternoon; her cooling vest and moving her seminars to the morning have helped. She has had no falls; on one hot afternoon in July her legs gave way briefly at home and her rollator caught her. Her bladder is better on mirabegron. She is preparing for the autumn term and several speaking engagements, and her university has put the accommodations she asked for in place. She had her bone density scan this morning. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 44 |
| Multiple sclerosis | Ocrelizumab started three months ago; walking unchanged; no relapse |
| Heat | Legs heavier in the afternoon heat; cooling vest helps |
| Mood | PHQ-2 0 |
Health risk assessment. Completed by the patient on the clinic's online form before the visit and reviewed with her by Dr. Moss. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good |
| Psychosocial | Engaged in her teaching and public work; good supports of her choosing; low stress apart from the term's start |
| Substance use | No tobacco; occasional alcohol within low-risk limits; no drug use |
| Physical activity | Home exercise program from physical therapy most days; pool exercise twice a week in cool water |
| Nutrition | Regular meals; dairy at most meals for calcium; takes vitamin D3 |
| Sleep | Seven hours; up once a night at most |
| Falls and home safety | No falls this year; one near-fall in the July heat; grab bars and a shower seat installed; no loose rugs |
| Driving | Drives safely by her account; no hand-control need at present |
| Work | Accessible room, chair and lectern, and reserved parking in place |
| Activities of daily living | Independent; tires by late afternoon |
| Seat belt and smoke alarms | Always wears a seat belt; smoke alarms tested |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue by late afternoon, worse in the heat; no fever or weight change |
| Eyes | Negative | No blurred or double vision |
| Ears, nose, mouth, and throat | Negative | No hearing change or sore mouth |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Regular bowels; no diarrhea |
| Genitourinary | Negative | Urgency improved; up once a night at most; no burning |
| Breast | Negative | No lump or nipple change |
| Musculoskeletal | Positive | Leg stiffness in the mornings, eased by stretching |
| Integumentary | Negative | No rash or cold sores |
| Neurological | Positive | Legs heavier in the heat, settling when she cools down; no new numbness or weakness lasting more than a day |
| Psychiatric | Negative | Mood steady; PHQ-2 0 |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-03-02 | active | S |
| Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated | One tablet three times a day | Oral route | 2026-03-16 to 2026-04-20 | completed | S |
| Baclofen 10 mg oral tablet, one tablet three times a day | One tablet three times a day | Oral route | 2026-04-20 | active | S |
| Mirabegron 25 mg extended-release oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center | 300 mg on day 1 and day 15 (given), then 600 mg every 6 months | Intravenous route | 2026-05-04 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-17 | Body height | 173 | cm | S |
| 2026-08-17 | Body weight | 83.4 | kg | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 27.9 | kg/m2 | S |
| 2026-08-17 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-08-17 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-17 | Heart rate | 74 | /min | S |
| 2026-08-17 | Respiratory rate | 16 | /min | S |
| 2026-08-17 | Body temperature | 36.7 | Cel | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-17 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-08-17 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-08-17 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 110 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-08-17 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 56 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-08-17 | Triglyceride [Mass/volume] in Serum or Plasma | 98 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-08-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 83.4 kg; blood pressure 118/74 |
| Eyes | Pupils equal and reactive; no nystagmus |
| Neck | No thyroid enlargement or lymph nodes |
| Breasts | Clinical breast examination with a chaperone, at her choice: no masses, skin or nipple changes, or axillary nodes |
| Cardiovascular | Regular rhythm; no murmur; no leg swelling |
| Respiratory | Clear |
| Abdomen | Soft, non-tender |
| Skin | No rash or suspicious lesions |
| Neurological | Spastic gait with the cane, as before; modified Ashworth 1+ in both legs; strength 4 out of 5 in the hip flexors; brisk leg reflexes |
| Psychiatric | Engaged and precise |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine | resolved | confirmed | G35.D | S — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts. |
| Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 2017 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosis | active | confirmed | G35.B1 | S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts. |
| Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls | active | confirmed | R26.89 | S — Synthetic modern coding anchored to her documented cane. |
| Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual | active | confirmed | N31.9 | S — Synthetic; common in multiple sclerosis. No public source describes her bladder. |
| Vitamin D deficiency | active | confirmed | E55.9 | S — Synthetic laboratory finding at intake. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 118/74 mmHg |
| Depression screening | Completed today | PHQ-2 score 0; PHQ-9 3 seven weeks ago |
| Unhealthy alcohol use screening | Completed today | Occasional use within low-risk limits |
| Tobacco use | Completed today | Never |
| Breast cancer screening | Ordered | Mammogram every two years from 40; no previous mammogram on file; ordered today, with the ocrelizumab label's advice to follow standard screening |
| Cervical cancer screening | Completed today | Primary HPV test with a chaperone present, after she was told each step and agreed; result by phone |
| Colorectal cancer screening | Not indicated | Begins at 45, next year; she prefers a stool test |
| Diabetes and lipid screening | Completed today | A1c 5.4%; total cholesterol 186, LDL 110, HDL 56, triglycerides 98 mg/dL; ten-year risk low, no statin |
| HIV and hepatitis C screening | Up to date | Both negative at intake |
| Bone density | Completed today | Z-scores -0.4 at the spine and -0.6 at the hip; done for reduced mobility and earlier steroid courses |
| Pneumococcal, zoster, Tdap and hepatitis B vaccines | Up to date | PCV20, both recombinant zoster doses, Tdap and both hepatitis B doses given before ocrelizumab |
| Influenza and COVID-19 vaccines, this season | Due | At the October review, at least two weeks before the next infusion |
| Live vaccines | Not indicated | Not recommended on ocrelizumab; varicella and measles immunity documented before treatment |
| Dental and eye examinations | Due | Dental review and an eye examination advised this year |
Guideline basis: OCREVUS (ocrelizumab) injection, prescribing information (2026); Adult Immunization Schedule by Age (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Cervical Cancer: Screening (2018)
Follow-up: Mammogram this month; HPV result by phone. Re-baseline brain MRI and the eight-month review in October, with influenza and COVID-19 vaccines. Next preventive visit in one year. Next scheduled visit 2026-10-26: eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work. [S]
Voluntary advance care planning discussion of about 20 minutes, with her consent. She wants full treatment for any illness that could be reversed, wants to be told plainly what is happening, and wants to make her own decisions. She named a health care agent, recorded in the confidential part of the chart and not named here, and asked that information about her health be shared only with the people she names. She chose not to record other treatment preferences today. To be revisited yearly or after any serious illness. [S]